Trial Profile
The outcome of gemcitabine, sorafenib and S1 combination in the treatment of inoperable hilar cholangiocarcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Nov 2016
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Sorafenib
- Indications Cholangiocarcinoma
- Focus Pharmacodynamics
- 12 Nov 2016 Status changed from not yet recruiting to completed.
- 28 Jul 2014 New trial record